Litigation Details for Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. (D. Del. 2022)
✉ Email this page to a colleague
Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. (D. Del. 2022)
Docket | ⤷ Sign Up | Date Filed | 2022-03-17 |
Court | District Court, D. Delaware | Date Terminated | 2023-08-30 |
Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
Jury Demand | Plaintiff | Referred To | |
Patents | 10,143,723; 10,172,808 | ||
Firms | Cooley LLP | ||
Link to Docket | External link to docket |
Biologic Drugs cited in Alnylam Pharmaceuticals, Inc. v. Moderna, Inc.
The biologic drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .
Details for Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. (D. Del. 2022)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
0000-00-00 | External link to document | |||
2022-03-17 | 1 | Exhibit 1-19 | granted European Patent, EP 3394093, by eleven issued U.S. patents, U.S. Patent Nos. 10,143,723, 10,172,808…solely-owned patent portfolio consists of more than 170 issued or allowed U.S. patents or patent applications…vaccination. This patent family includes two issued U.S. patents, two pending U.S. patent applications and…pending U.S. patent applications, five pending European patent applications, four pending patent applications…countries. Of these patent applications, a U.S. patent application and a Chinese patent application are allowed | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |